Modern tools and new evidence in staging of urothelial carcinomas
Poster Session 29
-
Location:Room Madrid, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session The proper diagnostic pathway, including demands for pathology and imaging, is an ongoing debate in bladder cancers.
Non-muscle invasive papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). New molecular biology techniques and clinical experience can pinpoint the highly malignant potential of selected CIS and T1 lesions. In muscle invasive bladder cancer both computed tomography (CT) and magnetic resonance imaging (MRI) may be used to detect T3b or higher disease. However, assessment of lymph node metastases with CT or MRI based on size and morphology has its limitations. This session aims to highlight new insights in the work-up of these tumors. - Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Institutes: 1Friedrich Schiller University of Jena, Dept. of Urology, Jena, Germany, 2Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, 3University Autonoma De Barcelona, Section of Pathology, Fundacio Puigvert, Barcelona, Spain, 4Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, 5Frederiksberg Hospital, Dept. of Urology, Frederiksberg, Denmark, 6Spanish National Cancer Research Centre, CNIO, Madrid, Spain, 7Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 8University of Aarhus, Dept. of Pathology, Aarhus, Denmark, 9University Hospital of Erlangen, Dept. of Pathology, Erlangen-Nürnberg, Germany, 10University Hospital Erlangen, Dept. of Urology, Erlangen, Germany, 11Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, 12Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Pathology, Munich, Germany, 13Faculty of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, 14Faculty of Medicine, University of Belgrade, Institute of Medical and Clinical Biochemistry, Belgrade, Serbia, 15Saarland University, Dept. of Urology, Homburg, Germany, 16Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, 17Aalborg University Hospital, Dept. of Pathology, Aalborg, Denmark, 18Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 19Klinikum Rechts Der Isar, Technical University of Munick, Dept. of Urology, Munich, Germany, 20Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 21Universitat Pompeu Fabra, Dept. of Experimental Science, Barcelona, Spain
Institutes: 1Turku University Hospital, Dept. of Urology, Turku, Finland, 2Turku University Hospital, Dept. of Diagnostic Radiology, Turku, Finland, 3University of Turku, Dept. of Information Technology, Turku, Finland, 4Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 5Tampere University Hospital, Dept. of Urology, Tampere, Finland, 6Turku University Hospital, Dept. of Clinical Oncology, Turku, Finland, 7Turku University Hospital, Dept. of Clinical Physiology, Nuclear Medicine and PET Imaging, Turku, Finland
Institutes: 1Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2University of Toronto, Princess Margaret Cancer Center, Dept. of Pathology, Toronto, Canada, 3University of Erlangen, Dept. of Pathology, Erlangen, Germany, 4University of Regensburg, Caritas Krankenhaus St. Joseph, Dept. of Urology, Regensburg, Germany, 5Hôpital Universitaire Pitié-Salpétrière, Dept. of Urology, Paris, France, 6Hôpital Universitaire Pitié-Salpétrière, Dept. of Pathology, Paris, France, 7Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 8University of Toronto, Princess Margaret Cancer Center, Dept. of Surgery (Urology), Toronto, Canada, 9Univerisity of Toronto, Mount Sinai Hospital, Dept. of Surgery (Urology), Toronto, Canada
Institutes: 1University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, 2University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, 3Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 4Mayo Clinic, Dept. of Urology, Rochester, United States of America, 5Sant’Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, 6IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, 7Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, 8University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, 9University Hospital of Ferrara, Nuclear Medicine Unit, Diagnostic Imaging E Laboratory Medicine Department, Ferrara, Italy, 10Sant’Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, 11Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy, 12University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy
Institutes: 1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, 3Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, 4Nakatsu Daiichi Hospital, Dept. of Urology, Nakatsu, Japan
Institutes: 1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 3University of Montreal, Dept. of Urology, Montreal, Canada, 4Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 5Faculty Hospital Motol, Second Faculty of Medicine, Charles University In Praha, Dept. of Urology, Prague, Czech Republic, 6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland
Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2L’Institut Mutualiste Montsouris, Dept. of Urology, Paris, France
Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada
Institutes: 1Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Narashino, Japan, 2Chiba University, Dept. of Urology, Chiba, Japan, 3Toho University Medical Center, Sakura Hospital, Dept. of Urology, Sakura, Japan, 4Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Sakura, Japan
Institutes: 1University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy, 2URI, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Sant’Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, 5University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, 6IRCCS Ospedale San Raffaele, Milan, Italy, Dept. of Nuclear Medicine, Milan, Italy, 7Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, 8S. Orsola-Malpighi Hospital, Dept. of Medical Oncology, Bologna, Italy, 9University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, 10University- Hospital of Ferrara, Dept. of Surgery, Ferrara, Italy, 11Sant’Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, 12Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy